OSIP » Topics » SIGNATURES

These excerpts taken from the OSIP 10-K filed Feb 27, 2009.
SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
OSI PHARMACEUTICALS, INC.
 
  By: 
/s/  COLIN GODDARD, Ph.D
Colin Goddard, Ph.D.
Chief Executive Officer
 
Date: February 27, 2009
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the days indicated.
 
             
Signature
 
Title
 
Date
 
         
/s/  ROBERT A. INGRAM

Robert A. Ingram
  Chairman of the Board   February 27, 2009
         
/s/  COLIN GODDARD, Ph.D.

Colin Goddard, Ph.D.
  Director and Chief Executive Officer (principal executive officer)   February 27, 2009
         
/s/  PIERRE LEGAULT

Pierre Legault
  Executive Vice President, Chief Financial Officer and Treasurer (principal financial and accounting officer)   February 27, 2009
         
/s/  SANTO J. COSTA

Santo J. Costa
  Director   February 27, 2009
         
/s/  DARYL K. GRANNER, M.D.

Daryl K. Granner, M.D.
  Director   February 27, 2009
         
/s/  JOSEPH KLEIN, III

Joseph Klein, III
  Director   February 27, 2009
         
/s/  KENNETH B. LEE, Jr.

Kenneth B. Lee, Jr.
  Director   February 27, 2009
         
/s/  VIREN MEHTA

Viren Mehta
  Director   February 27, 2009
         
/s/  DAVID W. NIEMIEC

David W. Niemiec
  Director   February 27, 2009
         
/s/  HERBERT PINEDO, M.D., Ph.D.
Herbert Pinedo, M.D., Ph.D.
  Director   February 27, 2009
         
/s/  KATHARINE B. STEVENSON

Katharine B. Stevenson
  Director   February 27, 2009
         
/s/  JOHN P. WHITE, ESQUIRE

John P. White, Esquire
  Director   February 27, 2009


109


Table of Contents

SIGNATURES


 



Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, as amended, the Registrant has
duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


 



OSI PHARMACEUTICALS, INC.


 
















  By: 

/s/  COLIN
GODDARD, Ph.D






Colin Goddard, Ph.D.



Chief Executive Officer


 



Date: February 27, 2009


 



Pursuant to the requirements of the Securities and Exchange Act
of 1934, as amended, this report has been signed below by the
following persons on behalf of the Registrant and in the
capacities and on the days indicated.


 
































































































































































































             


Signature


 


Title


 


Date

 

 

 

 

 

 

/s/  ROBERT
A. INGRAM


Robert
A. Ingram

 

Chairman of the Board

 

February 27, 2009

 

 

 

 

 

/s/  COLIN
GODDARD, Ph.D.


Colin
Goddard, Ph.D.

 

Director and Chief Executive Officer (principal executive
officer)

 

February 27, 2009

 

 

 

 

 

/s/  PIERRE
LEGAULT


Pierre
Legault

 

Executive Vice President, Chief Financial Officer and Treasurer
(principal financial and accounting officer)

 

February 27, 2009

 

 

 

 

 

/s/  SANTO
J. COSTA


Santo
J. Costa

 

Director

 

February 27, 2009

 

 

 

 

 

/s/  DARYL
K. GRANNER, M.D.


Daryl
K. Granner, M.D.

 

Director

 

February 27, 2009

 

 

 

 

 

/s/  JOSEPH
KLEIN, III


Joseph
Klein, III

 

Director

 

February 27, 2009

 

 

 

 

 

/s/  KENNETH
B. LEE, Jr.


Kenneth
B. Lee, Jr.

 

Director

 

February 27, 2009

 

 

 

 

 

/s/  VIREN
MEHTA


Viren
Mehta

 

Director

 

February 27, 2009

 

 

 

 

 

/s/  DAVID
W. NIEMIEC


David
W. Niemiec

 

Director

 

February 27, 2009

 

 

 

 

 

/s/  HERBERT
PINEDO, M.D., Ph.D.
Herbert
Pinedo, M.D., Ph.D.

 

Director

 

February 27, 2009

 

 

 

 

 

/s/  KATHARINE
B. STEVENSON


Katharine
B. Stevenson

 

Director

 

February 27, 2009

 

 

 

 

 

/s/  JOHN
P. WHITE, ESQUIRE


John
P. White, Esquire

 

Director

 

February 27, 2009









109





Table of Contents







EXCERPTS ON THIS PAGE:

10-K (2 sections)
Feb 27, 2009

RELATED TOPICS for OSIP:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki